Goldenrod Therapeutics, .

Goldenrod Therapeutics is developing next-generation, brain-penetrant phosphodiesterase 4 (PDE4) inhibitors for multiple neurological indications, including Friedreich’s ataxia, other neurodegenerative diseases, substance use disorders, and pain. Their oral, small molecule drugs are designed for high central nervous system exposure and improved tolerability, aiming to address significant unmet medical needs. Teams look it up for Biotech, Drug Discovery, HealthTech.